PMID: 7547092Jan 1, 1995Paper

The effect of tenidap sodium on the disposition and plasma protein binding of phenytoin in healthy male volunteers

British Journal of Clinical Pharmacology
R A BlumK D Wilner

Abstract

1. The effects of tenidap sodium 120 mg day-1 at steady state and placebo on the plasma protein binding and pharmacokinetics of phenytoin were compared in this randomised, double-blind, placebo-controlled, parallel-group study, involving 12 healthy young men, conducted over 34 days. 2. Single oral doses of phenytoin 200 mg were given on days 1-3 and 29-31, and intravenous phenytoin, 250 mg infused over 20 min, was given on days 4 and 32. Tenidap (120 mg day-1), or matching placebo, was administered as single oral daily doses from days 8 to 34 inclusive. 3. The plasma protein binding of phenytoin was determined immediately before oral phenytoin administration on days 1 and 29. Pharmacokinetic parameters were estimated from the serum phenytoin concentration-time curves derived on days 4 and 32 following the phenytoin infusions. The differences between the pre- and post-treatment mean percentage of unbound plasma phenytoin and mean pharmacokinetic parameters were compared between treatment groups. 4. Tenidap sodium 120 mg day-1, at steady state, increased the percentage of unbound phenytoin in plasma by approximately 25%, but did not significantly affect AUC(0,48h) or Cmax. 5. Since tenidap increases the percentage of unbound phen...Continue Reading

References

May 1, 1979·Clinical Pharmacokinetics·A Richens
Feb 1, 1990·The Biochemical Journal·P C HeinrichT Andus
Mar 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·M HattoriG H Fey
Mar 29, 1991·Biochemical and Biophysical Research Communications·M E VeroneseD J Birkett
Jul 1, 1989·Clinical Pharmacology and Therapeutics·P E NolanK Gear
Jan 1, 1995·British Journal of Clinical Pharmacology·G ApseloffN Gerber
Jan 1, 1995·British Journal of Clinical Pharmacology·K D Wilner, M J Gardner

❮ Previous
Next ❯

Citations

Jul 15, 1998·British Journal of Clinical Pharmacology·J O Miners, D J Birkett
Jul 1, 1992·British Journal of Clinical Pharmacology·M A TouchetteD J Edwards
Jan 1, 1995·British Journal of Clinical Pharmacology·K D Wilner, M J Gardner
Jan 1, 1995·Infectious Diseases in Obstetrics and Gynecology·L M Hollier, S M Cox
Jul 14, 2012·Drug, Healthcare and Patient Safety·Amy Z CrepeauElaine C Wirrell
Oct 10, 2006·Clinica Chimica Acta; International Journal of Clinical Chemistry·Amitava Dasgupta
Dec 13, 2002·Clinical Chemistry and Laboratory Medicine : CCLM·Amitava Dasgupta
Apr 27, 1999·Therapeutic Drug Monitoring·C Fedler, M J Stewart

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.